T2 Biosystems competitors

Mr. Matthew G. Molchan is President, Chief Executive Officer, Director of Digirad Corp. He was appointed as Chief Executive Officer, Director of the Company on July 1, 2013. He was previously Chief Operating Officer of Digirad Ultrascan Solutions from May 2007 to January 2012. He joined Digirad Ultrascan Solutions upon the acquisition of Ultrascan, Inc. by Digirad Corporation in May 2007. Prior to joining Digirad, Mr. Molchan was the CFO for Ultrascan, Inc - the southeast's mobile ultrasound business. Matt joined Ultrascan, Inc. in 2003. Prior to Ultrascan, Mr. Molchan held various executive level business development, finance and operations positions at Somera, Inc. and Equifax, Inc. Mr. Molchan holds a Bachelor of Science degree in Economics from the United States Air Force Academy and a Masters of Business Administration in finance from the University of Southern California.

Robert Kramer is a President & Chief Executive Officer at EMERGENT BIOSOLUTIONS INC., Board Member at EMERGENT BIOSOLUTIONS INC., and Interim Exec VP:Services at EMERGENT BIOSOLUTIONS INC. and is based in Lansing, Michigan. He has experience at PHARMACIA CORP and has worked as Pres:Biosciences Div at EMERGENT BIOSOLUTIONS INC., Consultant at EMERGENT BIOSOLUTIONS INC., and President at Emergent Biodefense Ops Lansg. Robert works or has worked as Chief Executive Officer at Emergent Biodefense Operations. He studied at WESTERN KENTUCKY UNIVERSITY between 1980 and 1983 and Clemson University between 1975 and 1979.

Francis Aurelio deSouza (born December 2, 1970) is an American entrepreneur and business executive. He is the president and chief executive officer (CEO) of Illumina and a member of the Board of Directors of The Walt Disney Company.

With a proven track record of bringing game-changing technologies to the market, Mr. Shamir joined Luminex Corporation as President, Chief Executive Officer, and Board Member in 2014. From 2006 to 2014, Mr. Shamir served as President and CEO of Given Imaging, a developer, manufacturer, and marketer of diagnostic products for the visualization and detection of disorders of the gastrointestinal tract, which was acquired by Covidien PLC in early 2014. Mr. Shamir currently serves on the board of directors of Exalenz Bioscience Ltd. (TASE: EXEN). He has previously served as a Board Member at Scitex Corporation, Cogentix Medical (NASDAQ: CGNT), recently acquired by Laborie Medical Technologies, and invendo medical GmBH, now part of Ambu. Mr. Shamir holds a Bachelor of Science from the Hebrew University of Jerusalem and a Masters of Public Administration from Harvard University.

Thomas Mika previously served as the Chairman of the Board of Rennova Health, the successor company to CollabRx and its predecessor, Tegal Corporation, a semiconductor capital equipment company. On the Board of Directors of Tegal since its spin-out from Motorola in 1989, Mika assumed the roles of Chief Financial Officer in 2002, CEO in 2005 and Chairman & CEO in 2006, positions which he held until 2015. In 2015, Tegal merged with Rennova Health with Mika retaining the position of Chairman until joining POET in November 2016. Previously, Mika co-founded IMTEC, a boutique investment and consulting firm, serving clients in the U.S., Europe and Japan over a period of 20 years, taking on the role of CEO in several ventures. Earlier in his career, Mika was a managing consultant with Cresap, McCormick & Paget and a policy analyst for the National Science Foundation. He holds a Bachelor of Science in Microbiology from the University of Illinois at Urbana-Champaign and a Master of Business Administration from the Harvard Graduate School of Business.

Speck Loe works at Medimmune and a Ceo at Medimmune and is based in Granite Falls, Washington.

Christophe Berthoux is an Exec VP:Global Sales & Mktg/Chief Commercial Ofcr at CHARLES RIVER LABORATORIES, Member of the Board of Directors at Synexus, and Chairman at IMAGE ANALYSIS INC and is based in London, Greater London, United Kingdom. He has worked as CEO at Synexus, Chief Executive Officer at Synexus Clinical Research Ltd, and Gen Mgr:Clinical Svcs at CHARLES RIVER LABORATORIES.

Jay Yadav is a ceo at CARDIOMEMS INC.